<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80656">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01969747</url>
  </required_header>
  <id_info>
    <org_study_id>1245.78</org_study_id>
    <secondary_id>2011-004354-25</secondary_id>
    <nct_id>NCT01969747</nct_id>
  </id_info>
  <brief_title>Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days</brief_title>
  <official_title>A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placebo-controlled, double blind (triple-dummy technique), randomised parallel design
      comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with
      T1DM as adjunctive therapy to insulin over 28 days. Patients will undergo a 14-day
      open-label placebo run-in period before randomisation. Background insulin therapy will be
      kept stable during the first 7 days of the treatment period and will be freely adjusted
      thereafter.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in 24 h UGE (g/24 h) after seven days of treatment with empagliflozin 2.5 mg, 10 mg, or 25 mg, or placebo</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Empagliflozin low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin low once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin medium once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin high once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin medium placebo</intervention_name>
    <description>Empagliflozin medium placebo</description>
    <arm_group_label>Empagliflozin high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin low placebo</intervention_name>
    <description>Empagliflozin low placebo</description>
    <arm_group_label>Empagliflozin medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin low placebo</intervention_name>
    <description>Empagliflozin low placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin high placebo</intervention_name>
    <description>Empagliflozin high placebo</description>
    <arm_group_label>Empagliflozin medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin medium</intervention_name>
    <description>Empagliflozin medium</description>
    <arm_group_label>Empagliflozin medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin medium placebo</intervention_name>
    <description>Empagliflozin medium placebo</description>
    <arm_group_label>Empagliflozin low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin high placebo</intervention_name>
    <description>Empagliflozin high placebo</description>
    <arm_group_label>Empagliflozin low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin high placebo</intervention_name>
    <description>Empagliflozin high placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin medium placebo</intervention_name>
    <description>Empagliflozin medium placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin low placebo</intervention_name>
    <description>Empagliflozin low placebo</description>
    <arm_group_label>Empagliflozin high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin low</intervention_name>
    <description>Empagliflozin low</description>
    <arm_group_label>Empagliflozin low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin high</intervention_name>
    <description>Empagliflozin high</description>
    <arm_group_label>Empagliflozin high</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed and dated written informed consent

          -  Male or female patient receiving insulin for treatment of T1DM for at least 12 months

          -  C-peptide &lt; 1.5 ng/mL

          -  Age 18 to 65 years

          -  HbA1c of 7.5% to 10.5%

          -  Multiple daily injections (MDI) of any type of insulin

          -  Willing to follow an established and individualized carbohydrate counting method and
             an insulin administration algorithm

          -  Body Mass Index of 18.5 to 35.0 kg/m2

          -  Estimated glomerular filtration rate 60 to 150 mL/min/1.73 mÂ²

          -  Able and willing to perform study assessments according to investigator's judgement

          -  Compliance with trial drug administration 80% to 120% during run-in period

          -  Willing not to take any paracetamol containing drugs during the trial

        Exclusion criteria:

          -  Acute symptomatic urinary tract infection or genital infection, chronic or recurrent
             cystitis

          -  History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY),
             pancreatic surgery or chronic pancreatitis

          -  Pancreas, pancreatic islet cells or renal transplant recipient

          -  Type 1 diabetes mellitus treatment with any other antihyperglycaemic drug except
             insulin within last 3 months or history of clinically relevant hypersensitivity

          -  Occurrence of hypoglycaemia that required hospitalization or treatment by an
             emergency physician or paramedic within last 3 months

          -  Hypoglycaemia unawareness or frequent episodes of unexplained hypoglycaemia

          -  Occurrence of diabetic ketoacidosis that required hospitalization or treatment by an
             emergency physician or paramedic within last 12 months

          -  History of macrovascular disease including cardiovascular, cerebrovascular and
             peripheral artery disease

          -  Autonomic neuropathy with gastroparesis

          -  Brittle diabetes

          -  Liver disease

          -  Treatment with anti-obesity drugs, surgery or aggressive diet regimen leading to
             unstable body weight

          -  Treatment with systemic corticosteroids

          -  Change in dose of thyroid hormones within last 6 weeks or planned change or
             initiation of such a therapy

          -  Medical history of cancer or treatment for cancer in the last five years

          -  Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells

          -  Alcohol or drug abuse that would interfere with trial participation or any ongoing
             clinical condition that would jeopardize patient's or site personnel's safety or
             study compliance

          -  Intake of an investigational drug in another trial within last 30 days

          -  Not able to understand and comply with study requirements

          -  Pre-menopausal women who are nursing or pregnant or of child-bearing potential and
             are not practising an acceptable method of birth control
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.78.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.78.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
